Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rNa-GST-1
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
rNa-GST-1 is a recombinant protein subunit vaccine candidate developed for the prevention of hookworm infection caused by *Necator americanus* and its associated complications, such as iron-deficiency anemia. The vaccine consists of a 24 kDa recombinant glutathione S-transferase-1 (Na-GST-1) antigen cloned from *N. americanus* and expressed in the yeast *Pichia pastoris*. Na-GST-1 is an essential enzyme in the hookworm's blood-feeding and hemoglobin digestion pathway, where it functions in heme and hematin detoxification. Immunization with rNa-GST-1, typically formulated with Alhydrogel (aluminum hydroxide) and adjuvants like CpG 10104 or GLA-AF, induces neutralizing antibodies that block the enzyme's catalytic and heme-binding activities, leading to parasite death or reduced fecundity. The vaccine has been evaluated in Phase 1 and Phase 2 clinical trials.
- Other names
- Formulation CNa-GST-1Na-GST1Na-GST 1Na-GST-1/Alhydrogelrecombinant Necator americanus Glutathione S-Transferase-1
02
Targets
Na-GST-1 (Glutathione S-transferase 1 from Necator americanus)
Beyond the preview
Go deeper on rNa-GST-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rNa-GST-1.